Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials

Arvinas Inc. (NASDAQ:ARVN) is one of the best cancer stocks to invest in now. On February 24, Arvinas Inc. (NASDAQ:ARVN) delivered solid fourth-quarter and full-year results that affirmed progress across pipeline development.

During the year, the company submitted its first new drug application, setting the stage for potential FDA approval of a PROTAC degrader. The company has already presented topline results for ARV-806, affirming robust and differentiated activity in models of KRAS G12D-mutated cancer. It is also progressing with dose escalation in the Phase 1 trial of ARV-393 in patients with non-Hodgkin’s lymphoma (NHL).393.

“With four ongoing clinical trials across our oncology and neurology portfolios, including the recently initiated first-in-human trial of our polyQ-AR degrader, ARV-027, we believe we have the potential to bring truly differentiated treatments to millions of patients in areas of significant unmet medical need,” said Randy Teel, Ph.D., President and CEO of Arvinas

Full year 2025 revenue came in at $262.6 million, down from $263.4 million a year ago. Fourth quarter revenue dropped to $9.5 million compared to $59.2 million in the same quarter of the prior year. The decrease was attributed to lower revenue from the Novartis license agreement.

Arvinas, Inc. (NASDAQ:ARVN) is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapies that degrade disease-causing proteins rather than just inhibiting them. Utilizing its proprietary PROTAC® (Proteolysis-Targeting Chimera) platform, the company targets “undruggable” proteins to treat serious, debilitating diseases, including prostate and breast cancers, as well as neurodegenerative disorders.

While we acknowledge the potential of ARVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.

Disclosure: None.  Follow Insider Monkey on Google News.